Hypoxia Dependent Inhibition of Glioblastoma Cell Proliferation, Invasion, and Metabolism by the Choline-Kinase

Claire Louise Kelly1,2, Martyna Wydrzynska2, Marie M Phelan3

  • 1Centre for Preclinical Imaging, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3BX, UK.

Metabolites
|February 25, 2025
PubMed

Insights

Hypoxia impacts glioblastoma treatment by affecting cellular metabolism and proliferation. JAS239, a choline kinase alpha inhibitor, shows potential against GBM, but its efficacy varies with cell line and oxygen levels.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metabolism

Background:

  • Elevated choline kinase alpha (ChoK) is common in solid tumors like glioblastoma (GBM).
  • ChoK inhibitors have shown limited efficacy in GBM models.
  • Tumor hypoxia may contribute to therapeutic resistance in GBM.

Purpose of the Study:

  • To investigate the impact of hypoxia on the efficacy of JAS239, a potent ChoK inhibitor.
  • To evaluate how hypoxia affects GBM cell proliferation, cell cycle, invasion, and metabolic pathways under JAS239 treatment.

Main Methods:

  • Utilized four GBM cell lines (rodent and human) under hypoxic conditions.
  • Treated cells with JAS239 and analyzed metabolic pathways using NMR.
  • Assessed cell proliferation, cell cycle, and invasion in 2D and 3D cultures.

Main Results:

  • Hypoxia and JAS239 altered phospholipid and glycolytic pathways.
  • JAS239 reduced GBM cell proliferation by inducing cell cycle arrest.
  • JAS239 also inhibited GBM cell invasion, though effects varied by cell line.

Conclusions:

  • JAS239 and hypoxia can deregulate GBM cellular metabolism, inhibit proliferation, and alter invasion.
  • Findings suggest potential for novel therapeutic strategies using ChoK inhibition for GBM.
  • Results highlight the need to consider tumor hypoxia in GBM treatment design.